Neurology Development Built Around Biotech Companies
Neurological development combines scientific complexity, long-term patient follow-up and specialist operational requirements, benefiting from integrated expertise across clinical, regulatory and scientific disciplines. Patient-centred development, multidisciplinary collaboration and consistent senior leadership throughout program delivery are central to successful neurological programs.
Evestia Clinical provides integrated scientific partnership and senior program leadership across Clinical Operations, Medical Affairs, Regulatory Affairs, Biostatistics and Clinical Data Management, through our Full-Service CRO model or embedded specialists via FSP Solutions.
Experienced Neurology Medical Specialists
Direct access to medical specialists with hands-on Phase I–IV & Post-Marketing experience across ALS, MND, neurodegenerative disorders and rare neurological diseases.
Senior Program Leadership
Consistent senior leadership throughout program delivery, providing scientific continuity, informed decision-making and direct collaboration at every milestone.
Integrated Scientific Expertise
Clinical Operations, Medical Affairs, Regulatory Affairs, Biostatistics, Medical Writing and Pharmacokinetics working as one coordinated neurology team.
Flexible Delivery Models
Scalable Full-Service CRO and Functional Service Provider (FSP) delivery aligned with program requirements and evolution.
Neurology Expertise at a Glance
These figures represent direct program experience across ALS, MND, neurodegenerative and rare neurological conditions, informing every operational, scientific and regulatory decision Evestia Clinical makes.
1,100+
Neurology Patients Supported
Across multiple neurological programs
120
Neurology Sites
Specialist neurology investigator centers
16
Countries
Global neurology trial delivery
ALS & MND
Specialist Expertise
Core neurodegenerative disease focus
* Based on combined Evestia Clinical and ARG neurology experience.
Scientific Considerations in Neurology Development
Successful neurology programs are shaped by specialist investigator networks, endpoint sensitivity over extended follow-up, imaging biomarker integration and adaptive statistical planning. Patient-centred development, caregiver engagement and digital health integration each contribute meaningfully to study quality and participant experience across long program timelines.
Digital health technologies and wearables are reshaping how functional outcomes are measured, creating important opportunities for more sensitive evidence generation. Our Global CRO capabilities support complex site networks across Phase I, Phase II and Phase III. Common program considerations include:
Bringing Innovative Neurological Therapies to Patients Requires More Than Operational Delivery
Successful neurological development depends on disease-specific scientific planning, specialist investigator engagement and integrated clinical expertise from protocol design through regulatory submission. Each neurological indication brings distinct scientific and operational requirements that benefit from therapeutic understanding embedded throughout the program.
Neurology sits alongside Oncology and Rare Disease as a strategic therapeutic focus at Evestia Clinical. Clinical Trial Management, Medical Affairs, Regulatory Affairs and Clinical Data Management work within one coordinated team throughout every program.
Supporting ALS and Motor Neuron Disease Development
ALS and MND represent areas of deep therapeutic focus within Evestia Clinical, and conditions of significant unmet need. Rapid disease progression narrows enrollment windows and concentrates the efficacy measurement period, requiring specialist operational planning, adaptive study design and disease-specific expertise across site selection and patient engagement.
Endpoint selection, from functional rating scales and respiratory assessments to survival endpoints, requires adaptive study designs and statistical approaches calibrated for limited, rapidly progressive populations. Specialist ALS and MND research centers, each with established investigator relationships and patient referral networks, are central to any credible recruitment strategy.
Many programs qualify for Fast Track, Breakthrough Therapy Designation and orphan regulatory pathways that support more efficient program progression through established regulatory pathways. Our Rare Disease CRO and Orphan Drug Development expertise ensures these incentives are integrated into program strategy from the outset.
Neurology Development Capabilities
Modern neurological development integrates digital biomarkers, wearables, imaging endpoints and patient-reported outcomes alongside traditional assessments. The capabilities below reflect how that complexity is managed across every neurology program.
ALS & MND Expertise
Supporting programs focused on Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND) and related neurodegenerative conditions, with adaptive study design and patient-focused operational planning throughout.
Adult & Pediatric Experience
Supporting neurological development programs across diverse patient populations, from pediatric-onset conditions through to late-onset neurodegenerative diseases, with specialist operational approaches for each.
Phase I–IV & Post-Marketing Development Support
Providing comprehensive support throughout every stage of clinical development, from first-in-human studies through to multinational registration programs, with consistent specialist neurology teams throughout.
Emerging Neurology Technologies
Working alongside sponsors integrating digital biomarkers, wearable technologies, imaging endpoints and patient-reported outcomes into modern neurological development programs.
Neurology Clinical Trial Services
Integrated scientific collaboration, multidisciplinary delivery and coordinated program leadership support endpoint consistency and scientific quality across the long timelines neurological programs require. Every service below is delivered within one coordinated neurology team, aligned towards the same program outcome.
Clinical Trial Management
Providing program leadership, vendor management and operational oversight throughout complex neurology studies from initiation through close-out.
Learn moreClinical Operations
Integrated clinical operations support across neurology programs, coordinating investigators, sites, vendors and study activities throughout the development lifecycle.
Learn moreClinical Monitoring
Supporting investigator sites while maintaining protocol compliance, patient safety and data quality across geographically dispersed neurology site networks.
Learn moreClinical Site Management
Working closely with specialist neurology centers and investigators to optimize site performance, patient recruitment and site engagement throughout each study.
Learn moreStudy Start-Up Services
Accelerating site feasibility, selection and activation to reduce timelines from protocol development to first patient enrolled in neurology studies.
Learn moreRegulatory Affairs
Helping sponsors navigate global regulatory requirements, neurological development pathways and orphan drug designation strategies for rare neurological conditions.
Learn moreClinical Data Management
Managing complex neurological datasets, imaging outputs, cognitive assessment data and long-term follow-up information with CDISC-compliant outputs.
Learn moreBiostatistics
Supporting endpoint strategy, statistical analysis plans and submission-ready reporting for neurology studies including longitudinal designs and complex endpoints.
Learn moreMedical Affairs
Physician-led medical monitoring, medical strategy and safety review providing therapeutic expertise throughout neurology development.
Learn morePharmacovigilance
Providing comprehensive safety oversight across neurological clinical development programs and post-marketing activities.
Learn moreMedical Writing
Preparing protocols, investigator brochures, clinical study reports, regulatory documentation and orphan drug application support for neurology programs.
Learn morePharmacokinetics
Supporting PK modeling, exposure-response analysis and dose optimization strategies for neurological therapies including CNS drug development.
Learn moreFSP Solutions
Dedicated embedded neurology specialists available through our Functional Service Provider model for sponsors requiring flexible resource scaling.
Learn moreExpertise Across Neurological Disorders
Each neurological indication presents distinct scientific, operational and regulatory considerations. Disease-specific neurology expertise and integrated scientific leadership support programs across:
Amyotrophic Lateral Sclerosis (ALS)
Supporting innovative therapies targeting disease progression and patient outcomes in ALS. Rapidly progressive disease pathways and specialist site requirements benefit from dedicated ALS operational experience and disease-specific program planning.
Motor Neuron Disease (MND)
Providing scientific and operational expertise for complex MND development programs, including endpoint strategy, specialist site selection and patient recruitment planning tailored to the scientific requirements of this indication.
Neurodegenerative Disorders
Supporting development programs investigating progressive neurological decline, including Parkinson's disease, Alzheimer's disease and Huntington's disease, with longitudinal study designs and specialist assessment management.
Rare Neurological Diseases
Combining Neurology and Rare Disease CRO expertise for sponsors developing treatments for orphan neurological conditions, where small populations, global recruitment and regulatory incentive strategies are all critical.
Cell & Gene Therapy Neurology Programs
Supporting advanced therapies targeting neurological and genetic disorders through our integrated Cell & Gene Therapy CRO capabilities, combined with specialist neurology program knowledge.
Supporting Neurology Programs from Early Development Through Regulatory Submission
Scientific continuity strengthens neurological development by preserving program knowledge, endpoint consistency and regulatory alignment across every phase. The safety data from Phase I, the biomarker stratification decisions from Phase II and the endpoint frameworks established at the outset all shape the quality of Phase III evidence.
The same specialists remain engaged as programs advance, with Regulatory Affairs aligned from the outset and consistent Clinical Trial Management from Phase I through to Phase III registration.
Cell and Gene Therapy for Neurological Disorders
Gene therapies and cell-based approaches are increasingly being investigated for rare genetic neurological disorders, ALS, spinal muscular atrophy and CNS lysosomal storage diseases. These programs require specialist operational approaches and integrated scientific expertise: one-time dosing logistics, long-term safety follow-up extending years post-treatment and gene expression monitoring strategies.
Our Cell & Gene Therapy CRO capabilities are fully integrated with neurology knowledge, giving sponsors a single team that understands both the therapeutic context and the operational demands of advanced neurological therapy development.
Neurology Development Across Every Phase
First-in-human studies and dose escalation in neurology, with protocols designed around the specific safety considerations and assessment requirements of neurological patient populations.
Learn moreProof-of-concept, dose optimization and adaptive designs that establish meaningful efficacy signals and biomarker-driven evidence in complex neurological populations.
Learn moreMultinational registration programs coordinated across specialist neurology centers worldwide, with consistent quality and operational oversight throughout.
Learn moreRare Disease and Neurology Expertise Combined
ALS, rare neuromuscular diseases and rare genetic neurological disorders sit at the intersection of neurology and rare disease. Sponsors benefit from integrated Rare Disease and Neurology expertise delivered within one coordinated scientific team. Combining our Rare Disease CRO and Neurology CRO capabilities, we help sponsors navigate:
- Small patient populations
- Complex recruitment strategies
- Patient advocacy engagement
- Orphan drug opportunities
- Global investigator networks
This integrated approach provides sponsors with a stronger foundation for successful development across rare neurological programs. Explore our Orphan Drug Development capabilities for programs qualifying for regulatory incentives and accelerated development pathways.
How Evestia Strengthens Neurology Development
Integrated scientific expertise, collaborative program delivery and consistent neurology leadership support confident development decisions and regulatory success across long neurology program timelines.
Progressive Neurological Diseases
ALS and MND narrow enrollment windows and concentrate efficacy measurement periods, requiring specialist planning and coordinated program leadership. Disease-specific operational experience and established site networks support confident delivery throughout these rapidly progressive conditions.
Biomarker-Driven Development
Imaging biomarkers, fluid biomarkers and molecular endpoints define evidence generation in modern neurology. Integrating MRI, PET and biofluid data requires specialist data management and statistical frameworks built for longitudinal neurological evidence.
Specialist Patient Recruitment
Neurological patients are concentrated at specialist centers and academic institutions. Established investigator networks and disease-specific expertise strengthen recruitment strategy and support retention across long-duration neurology studies.
Rare Neurological Disorders
Many neurological conditions qualify as orphan indications. Combined Neurology and Rare Disease CRO expertise within one team provides a stronger foundation where small populations, global coordination and regulatory incentive strategies are all important.
Longitudinal Evidence Generation
Long study durations require consistent scientific oversight and coordinated operational delivery throughout long-term follow-up. Digital health integration, standardized assessment administration and strong investigator relationships maintain data quality and participant retention across extended programs.
Scalable Neurology Expertise
As neurology portfolios evolve, access to embedded scientific expertise and integrated partnership becomes a strategic priority. Full-Service CRO delivery and Functional Service Provider (FSP) specialists provide the depth and program flexibility needed at each stage of development.
Why Sponsors Choose Evestia Clinical for Neurology Clinical Trials
The neurology CRO a sponsor chooses shapes more than operational execution. It shapes the quality of every endpoint decision, the strength of every regulatory submission and the confidence with which a program approaches its most important milestones. As a specialist Biotech CRO, Evestia Clinical is structured to provide the scientific depth, senior access and operational agility that complex neurological programs demand.
Neurology Knowledge Embedded in Every Program
Deep therapeutic knowledge across ALS, MND, neurodegenerative disorders and rare neurological diseases, built across direct program experience. Experienced scientific guidance embedded throughout program delivery provides the foundation that complex neurological programs require.
ALS & MND Leadership
Core therapeutic focus in Amyotrophic Lateral Sclerosis and Motor Neuron Disease development, including functional endpoint strategy, specialist site networks, adaptive study design and patient-focused operational planning for these rapidly progressive conditions.
Integrated Rare Disease and Neurology Expertise
Rare Disease CRO capabilities combined with neurology expertise, providing sponsors with orphan designation strategy, small population trial design and regulatory incentive planning for rare neurological conditions within one integrated team.
Delivering Global Neurology Programs With Confidence
Established global site networks, multinational operational experience and international regulatory knowledge support access to dispersed neurological patient populations and coordinated international neurology programs through established investigator networks and coordinated global program leadership.
A Scientific Partner Built for Biotechnology Companies
Senior-led program delivery, direct communication and integrated scientific collaboration give biotechnology organizations the responsiveness they need to support confident program progression and informed development decisions throughout the lifecycle.
Flexible Partnerships That Scale With Your Program
Neurology programs supported through our Full-Service CRO model or via dedicated embedded resources through FSP Solutions, providing sponsors with the flexibility to scale scientific expertise as program requirements and program evolution demand.
Scalable Embedded Neurology Expertise
Dedicated neurology specialists available through our FSP Solutions model, providing experienced CRAs, trial managers and scientific professionals embedded within sponsor teams for scalable embedded neurology expertise aligned with sponsor requirements.
Neurology CRO Support for Biotech Companies
Biotechnology companies advancing neurology programs need scalable scientific expertise, long-term collaborative partnership and the flexibility to access both throughout extended development cycles. Evestia Clinical provides integrated scientific partnership supporting neurology programs from Phase I through registration.
Scientific continuity and program knowledge are preserved throughout, with consistent specialist engagement from early development through to regulatory submission. Available through our Full-Service CRO model or embedded FSP specialists, and structured as a dedicated Biotech CRO, Evestia Clinical is built for the long development cycles that neurological innovation requires.
Frequently Asked Questions About Neurology CRO Services
Explore Related Clinical Development Services
Service Pages
Development Phases
Related Therapeutic Expertise
Helping Neurology Innovators Advance Life-Changing Therapies
ALS and MND leadership, integrated neurology expertise and collaborative partnership from first-in-human studies to global registration. Evestia Clinical is the neurology development partner built for the long timelines, patient-centred innovation and scientific rigor that define this therapeutic area.